当前位置:首页 - 行情中心 - 益佰制药(600594) - 财务分析 - 利润表

益佰制药

(600594)

  

流通市值:37.62亿  总市值:37.62亿
流通股本:7.92亿   总股本:7.92亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入2,136,834,252.041,479,701,367.04683,797,926.882,735,262,838.67
营业收入2,136,834,252.041,479,701,367.04683,797,926.882,735,262,838.67
二、营业总成本1,930,208,223.551,316,998,284.2622,690,981.422,525,487,621.06
营业成本627,805,844.57425,615,160.01218,757,536.19794,229,306.03
税金及附加33,943,469.923,135,621.5112,203,357.3937,966,134.99
销售费用936,756,363.4650,985,213.32296,510,922.851,195,795,849.97
管理费用246,765,695.89166,309,814.0671,893,742.63337,248,947.98
研发费用73,852,804.2348,369,912.1622,461,952.84126,933,083.42
财务费用11,084,045.562,582,563.14863,469.5233,314,298.67
其中:利息费用14,392,620.024,793,313.2481,666.8237,475,528.74
其中:利息收入4,793,286.543,181,445.771,194,000.787,320,687.48
加:投资收益113,142.6523,930.43-116,696.04-166,346.68
资产处置收益16,639.1116,639.11-31,049,336.4
资产减值损失(新)-27,429,216.25-20,925,686.57-13,715,780.43-643,840,312.65
信用减值损失(新)1,003,915.2973,208.721,174,637.34869,562.89
其他收益18,977,405.1612,952,450.76,029,827.9726,347,342.01
营业利润平衡项目0000
四、营业利润199,307,914.36155,743,625.2354,478,934.3-375,965,200.42
加:营业外收入1,201,830.03196,016.817,181.371,816,310.17
减:营业外支出5,602,198.222,297,301.031,774,805.6217,917,123.62
利润总额平衡项目0000
五、利润总额194,907,546.17153,642,34152,721,310.05-392,066,013.87
减:所得税费用33,407,638.8631,913,947.3911,213,344.5246,261,440.9
六、净利润161,499,907.31121,728,393.6141,507,965.53-438,327,454.77
持续经营净利润161,499,907.31121,728,393.6141,507,965.53-438,327,454.77
归属于母公司股东的净利润169,869,961.21127,906,049.2943,999,942.75-426,467,196.36
少数股东损益-8,370,053.9-6,177,655.68-2,491,977.22-11,860,258.41
(一)基本每股收益0.220.160.06-0.54
(二)稀释每股收益0.220.160.06-0.54
八、其他综合收益-343,624.32--145,618.76-198,340.25
归属于母公司股东的其他综合收益-343,624.32--145,618.76-198,340.25
九、综合收益总额161,156,282.99121,728,393.6141,362,346.77-438,525,795.02
归属于母公司股东的综合收益总额169,526,336.89127,906,049.2943,854,323.99-426,665,536.61
归属于少数股东的综合收益总额-8,370,053.9-6,177,655.68-2,491,977.22-11,860,258.41
公告日期2023-10-272023-08-182023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑